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ABSTRACT
Background: It has been known that vitamin D level (serum 25[OH]D) has correlation with 
inflammatory bowel disease (IBD). The purpose of this study is to investigate changes of 
serum 25[OH]D in pediatric IBD patients according to the disease activity.
Methods: A total of 96 children and adolescent with IBD were enrolled in this retrospective 
study. Serologic inflammatory markers and clinical disease activity scores of the patients were 
collected, and their correlations with serum 25[OH]D were analyzed. Seasonal variations of 
serum 25[OH]D were also investigated both in active disease state and remission state.
Results: Of the 96 patients, 41 (43%) were women and patients with a vitamin D deficiency 
(< 20 ng/mL) at diagnosis were 77 (80.2%). There was no significant difference between 
Crohn's disease and ulcerative colitis for serum 25[OH]D. Serum 25[OH]D was higher in 
remission group than in active disease group (12.4 [8.8–29] ng/mL vs. 17.9 [12.3–34.4] ng/mL; 
P < 0.001) and the difference was more significant than other micronutrients. There was no 
significant difference in serum 25[OH]D concentration between patients with ileal involvement 
and patients without ileal involvement. There were seasonal variations in the active phase, but 
there was no significant difference by season in the remission phase.
Conclusion: Serum 25[OH]D is inversely correlated with disease activity in IBD. Monitoring 
and supplementation is required especially for active disease status and in winter and spring 
season.
Keywords: Vitamin D; Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis; 
Disease Activity; Pediatric
INTRODUCTION
Inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) and ulcerative colitis 
(UC), are chronic inflammatory diseases that involve the gastrointestinal tract.1 Although 
the pathogenesis and etiology of IBD are not well understood, it has been hypothesized 
that its pathogenesis involves environmental and genetic factors.2 Impaired immunity in 
response to the intestinal flora and antigens are thought to cause chronic inflammation in 
the alimentary tracts.2,3
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Malnutrition is found in up to 85% of patients with IBD, in the active and remission 
phases. Micronutrient deficiencies are present in more than half of patients with IBD. The 
deficiencies are more frequent in CD than in UC and in active disease than in remission.4 The 
most common micronutrients deficiencies in IBD are vitamin B12, folate, iron, and especially 
vitamin D.
Vitamin D is known as the most important regulator of calcium (Ca) and phosphorus 
(P) metabolism related to bone health but studies suggest the new role of vitamin D 
in immunomodulation recently,5 and Vitamin D is even proposed as a treatment for 
autoimmune diseases such as multiple sclerosis,6 systemic lupus erythematous,7 and IBD.8 
Furthermore Ananthakrishnan et al.9 has reported that vitamin D deficiency may play a role 
in the increased risk of malignancies in IBD. However, limited studies have been conducted 
about the relationship between vitamin D and disease activity in IBD over a multi-year period, 
especially in pediatric patients so far.
Therefore, we aimed to investigate the association of vitamin D with disease activity and 
clinical course in pediatric patients with IBD.
METHODS
Patients
Our study was performed in the Pediatric Gastroenterology, Hepatology and Nutrition Clinic 
of Severance Children's Hospital for patients diagnosed with UC or CD from September 2012 
to April 2018.
Patients younger than 19 years of age who were diagnosed with CD or UC according to the 
Revised Porto Criteria and underwent regular follow-up were included in this study. Patients 
diagnosed with IBD unclassified, patients who did not undergo blood tests including vitamin 
D during the active and remission phases, patients with insufficient medical records, and 
patients with vitamin D supplementation were excluded.
Data collection
The medical records of the enrolled patients were retrospectively analyzed. Clinical records 
and laboratory test results during the active and remission phases were collected for each 
patient. We recorded the highest disease activity score and longest duration of remission 
in cases when there were multiple active phases or remission phases in one patient. In this 
study, the active phase was defined as when the disease activity score (Pediatric Crohn's 
Disease Activity Index [PCDAI] or Pediatric Ulcerative Colitis Activity Index [PUCAI]) was 10 
or more. The remission phase was defined as the period when the patient's clinical symptoms 
were relieved and the disease active score remained below 10 points for more than 3 months 
without the use of steroids.
Biochemical assessment
Our registry includes demographic, laboratory, clinical, endoscopic, radiological, and 
pathological data of the enrolled patients, and it is updated routinely. Clinical records and 
disease activity scores documented at 2 to 6-month intervals were collected for each patient. 
Serologic markers of inflammation, including the C-reactive protein (CRP) level, erythrocyte 
sedimentation rate (ESR), and white blood cell (WBC), as well as levels of serum Ca/P, folate, 
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vitamin B12, zinc, albumin, pre-albumin, and vitamin D were collected. To evaluate patients' 
vitamin D status, the serum level of 25-hydroxyvitamin D 25[OH]D was measured using the 
liquid chromatography-tandem mass spectrometry in the clinical laboratory.
Patients were classified based on their serum 25[OH]D level. Vitamin D deficiency was 
defined as a 25[OH]D level < 20 ng/mL, insufficiency as 21–29 ng/mL, and normal or 
sufficient as > 30 ng/mL.10-12
Statistical analysis
Laboratory data for CD and UC, and laboratory data for active and remission phases were 
analyzed using the Mann-Whitney U test. The changes of active and remission phases in each 
patient were analyzed using the paired t-test. We compared the vitamin D levels of an age-
matched healthy control group from the Korea National Health and Nutrition Examination 
Survey and those of our study patients with IBD by using the Student's t-test. Vitamin D levels 
in the active and remission phases were compared using the Kruskal-Wallis test for each 
season (spring, summer, fall, and winter).
All statistical analyses were performed using the SPSS software (version 23.0; IBM Corp., 
Armonk, NY, USA). The 95% confidence interval is reported where relevant. Two-sided  
P values of < 0.05 were considered statistically significant.
Ethics statement
The protocol of this study was approved by the Institutional Review Board (IRB) of Severance 
Hospital (IRB approval No. 4-2018-1044). Because this was an observational study without 
intervention and without the presentation of any identifying data, the committee ruled that 
informed consent was unnecessary.
RESULTS
Ninety-six patients with IBD (72 patients with CD, 24 patients with UC) formed the 
study population. Table 1 shows the study population's basic demographics, clinical 
characteristics, and data on vitamins. There was a significant difference in gender between 
the patients with CD and those with UC. A higher percentage of man patients had CD, 
whereas a higher proportion of woman patients had UC.
As shown in Table 2, there was no significant difference between CD and UC for serum 
25[OH]D. The inflammatory markers were elevated in patients with UC and CD during the 
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Table 1. Demographic data and characteristics of patient
Variables Overall (n = 96) CD (n = 72) UC (n = 24) P value
Women 41 (42.7) 26 (36.1) 15 (62.5) 0.022
Age at diagnosis, yr 13.1 (12.0–15.0) 13.2 (12.0–15.0) 13.1 (12.0–18.0) 0.986
Duration between active and remission, mon 21.2 (12.0–26.0) 20.9 (11.0–42.0) 22.1 (13.0–35.0) 0.612
Ileum involvement 68 (72.3) 68 (94.4) 0 (0.0) N/A
Disease activity score
Active N/A 40.1 (30.0–50.0) 39.5 (20.0–55.0) N/A
Remission N/A 2.2 (0.0–5.0) 1.5 (0.0–0.0) N/A
Values are presented as No. (%) or median (interquartile range). Disease activity score was based on Pediatric 
Crohn's Disease Activity Index and Pediatric Ulcerative Colitis Activity Index scores.
CD = Crohn's disease, UC = ulcerative colitis, NA = not applicable.
active phase compared to those during the remission phase. Additionally, the inflammatory 
markers were higher in patients with CD than in those with UC during both phases.
Ca, P, and albumin levels remained relatively unaffected by disease activity in patients with 
UC. These micronutrients were lower in the active phase and showed a tendency to recover 
well during the remission phase in patients with CD.
In patients with UC and CD, folate and zinc levels showed a tendency to be dependent on 
disease activity, as they decreased in the active phase and increased in the remission phase. 
These micronutrients tended to recover well during the remission phase in patients with UC, 
but less recovery was shown in patients with CD. Specifically, vitamin B12 was higher in the 
active phase than in the remission phase.
Vitamin D in patients with UC and CD showed a significant difference according to disease 
activity. In particular, the vitamin D level was higher in the remission phase than in the active 
phase, but it remained in “insufficiency” status.
Except for vitamin B12, the other micronutrients showed a tendency to increase significantly 
in the remission phase than in the active phase according to the paired t-test. Vitamin D 
showed a larger difference in remission and active phases than other micronutrients when 
evaluated using fold-change measurements (Fig. 1).
IBD patients in the active phase showed a lower mean vitamin D level than the healthy control 
group and remission phase group. Vitamin D levels of the remission phase group and control 
group based on youth in the Korea National Health and Nutrition Examination Survey of 2015 
were similar (Fig. 2).
However, there was no statistically significant difference in the vitamin D level during the active 
phase whether or not IBD involved the ileum (12.45 ng/mL and 11.91 ng/mL, respectively).
Finally, measured vitamin D levels in active phase and remission phase were sub-grouped 
according to the measured season. There were seasonal variations in the active phase, but 
there was no significant difference by season in the remission phase (Fig. 3).
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Table 2. Laboratory findings in inflammatory bowel disease patients in active phase and remission phase
Variables Comparison between CD and UC,  
remission phase
Comparison between CD and UC,  
active phase
Comparison between active 
and remission phase
CD (n = 72) UC (n = 24) P value CD (n = 72) UC (n = 24) P value P value, CD P value, UC
WBC, 103/μL 6,505  
(5,182.50–7,787.50)
6,210  
(4,760.00–7,525.00)
0.356 8,965  
(7,072.50–10,437.50)
7,735  
(6,610.00–10,425.00)
0.212 < 0.001a 0.002 a
ESR, mm/hr 21.50 (9.50–35.75) 13.50 (6.25–28.75) 0.087 71.50 (38.50–90.50) 39.00 (16.75–73.25) 0.005a < 0.001a < 0.001a
CRP, mg/L 1.50 (0.53–4.85) 0.40 (0.40–0.50) < 0.001a 32.50 (16.85–59.40) 1.87 (0.98–13.68) < 0.001a < 0.001a 0.001a
Ca, mg/dL 9.20 (9.03–9.30) 9.15 (9.00–9.38) 0.660 8.80 (8.50–9.10) 9.25 (9.00–9.53) 0.016a < 0.001a 0.831
P, mg/dL 4.40 (4.00–4.90) 4.20 (3.80–4.85) 0.716 4.25 (3.83–4.58) 4.55 (4.18–4.93) 0.099 0.010a 0.717
Albumin, g/dL 4.30 (4.10–4.50) 4.30 (4.03–4.60) 0.494 3.50 (3.03–3.80) 4.05 (3.70–4.50) 0.001a < 0.001a 0.023a
Pre-albumin, mg/L 209.50 (175.50–231.75) 260.00 (200.50–290.50) 0.066 133.00 (92.00–167.00) 172.00 (156.50–215.50) 0.066 0.002a 0.005a
Folate, ng/mL 8.14 (5.81–10.33) 10.60 (7.97–17.29) 0.042a 7.66 (5.00–10.40) 7.96 (6.26–11.63) 0.938 0.173 0.022a
Vitamin B12, pg/mL 389.00 (299.25–547.00) 567.00 (381.75–703.50) 0.002a 511.00 (400.00–691.00) 603.00 (414.25–913.25) 0.466 < 0.001a 0.064
Zinc, mcg/dL 74.90 (68.00–86.18) 87.75 (78.60–101.90) < 0.001a 72.80 (59.95–80.90) 79.90 (68.70–88.03) 0.148 0.056 0.004a
Serum 25[OH]D, ng/mL 17.50 (12.70–20.42) 19.36 (10.99–23.82) 0.348 12.41 (8.83–15.32) 12.51 (7.44–19.73) 0.611 < 0.001a 0.026a
Values are presented as median (interquartile range).
CD = Crohn's disease, UC = ulcerative colitis, WBC = white blood cell, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, Ca = calcium, P = phosphorus.
aP value < 0.05, statistically significant.
DISCUSSION
Many studies have been conducted on malnutrition and micronutrient deficiencies due to 
the reduction of oral intake and increased gastrointestinal losses of nutrients in patients 
with IBD.13 Several studies have reported micronutrient deficiency in IBD and analyzed 
the relationship between nutritional deficiency and body mass index or body fat in IBD 
patients.14,15
Especially many studies have conducted regarding vitamin D in IBD and some reports 
suggested that vitamin D regulates the secretion and inhibition of cytokines involved in 
the inflammatory response in immune systems as well as Ca homeostasis.16-18 Therefore, 
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Fig. 1. Comparison of vitamin D and micronutrients (combined standard). Vitamin D showed a larger difference in 
remission and active phases than other micronutrients when evaluated using fold-change measurements.
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Fig. 2. Comparison of vitamin D difference in active, remission and control group. Inflammatory bowel disease 
patients in the active phase showed a lower mean vitamin D level than the healthy control group and remission 
phase group. Vitamin D levels of the remission phase group and control group based on youth in the Korea 
National Health and Nutrition Examination Survey of 2015 were similar.
it is important to supplement vitamin D and micronutrients in the treatment of IBD.19,20 
However, these malnutrition and micronutrient deficiencies have not been studied in 
pediatric patients with IBD, even though these patients should be treated immediately to 
prevent adverse effects on their growth and development.
Our study showed that inflammatory markers, e.g., WBC, ESR, and CRP, are more elevated in 
CD than in UC, and this tendency was observed in the active and remission phases.
Ca, P, and albumin were not significantly affected by disease activity in UC, whereas they 
remained significantly lower in the active phase than in the remission phase of CD and 
recovered well at the time of remission. In patients with UC and CD, folate and zinc levels 
showed a correlation with disease activity. They decreased in the active phase and increased 
in the remission phase. It is thought that IBD, especially CD, involving the small intestine, 
which is the site of folate and zinc absorption, affects the terminal ileum and increases folate 
and zinc deficiencies.21-23
Interestingly, our study showed that vitamin B12 was higher in the active phase than 
in the remission phase. This finding is different from results of other studies in which 
micronutrients were found to be lower in the active phase and in CD.24 However for the 
accurate assessment of vitamin B12 deficiency, functional studies of homocysteine (low 
level) or methylmalonic acid (high level) are necessary.25 Although additional functional 
studies should have been performed in our study, we think that vitamin B12 is less affected by 
inflammatory activity than other micronutrients.
Our results confirmed the findings of previous studies that reported a high prevalence 
of vitamin D deficiency in IBD.26,27 Although the mechanism is still unclear, vitamin D 
deficiency may be associated with an increased IBD activity score, lower sun exposure, and 
decreased absorption from inflammatory mucosa.18,28,29 In our study, the vitamin D level 
was higher in the remission phase than in the active phase in UC and CD. The reason for the 
increased vitamin D level in the remission is unclear, but is probably a result of a combination 
of increased nutritional intake, increased outdoor activity and reduced need for steroid 
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Fig. 3. Seasonal variation of vitamin D. There were seasonal variations in the active phase, but there was no significant difference by season in the remission phase.
therapy.28,30 Because previous studies have suggested that steroids may enhance inactivation 
of 25[OH]D by promoting 24-hydroxylase activity.31 Also, as the disease improves, increased 
level of vitamin D will help the inducing or maintaining of remission by improving anti-
inflammatory and immune-mediated regulation. Indeed, our study show that vitamin D 
level was similar in those who did and did not have ileocecal valve resection. Bile acid, which 
is known to be involved in lipid-soluble vitamin absorption, is reabsorbed through ileum. 
These results indicate that vitamin D deficiency in IBD is mostly related with disease activity 
rather than decreased absorption due to inflammation of the small intestine. Therefore, in 
order to prevent various complications of vitamin D deficiency, it is important to maintain a 
prolonged remission state by controlling the activity of IBD.
Compared to other micronutrients, vitamin D levels tended to show a larger difference 
depending on disease activity. This result suggests that vitamin D deficiency itself in IBD 
may lead to disease aggravation. Recent studies have shown that vitamin D is involved in the 
immune system and inflammatory response by inhibiting the regulation of inflammatory 
cytokines and differentiation of proinflammatory cells.32,33 Further, other studies 
demonstrated an experimental link between vitamin D status and severity of IBD in animals: 
vitamin D deficiency exacerbated the symptoms and severity of enterocolitis in interleukin-10 
knockout mice, whereas supplementation with vitamin D ameliorated IBD symptoms, 
reduced inflammation, and improved histologic scores and mortality.34
According to Garg et al.,35 fecal leukocytes (e.g., calprotectin) more closely reflect intestinal 
inflammation than systemic markers (e.g., CRP, ESR, and WBC). They also reported an 
inverse correlation between the levels of vitamin D and calprotectin in patients with IBD. 
These findings support the theory that serum 25[OH]D may affect local tissue inflammation. 
Thus, vitamin D supplementation may need to be studied as a drug for regulating IBD 
inflammation and providing nutritional support.
In our study, patients in the active phase showed seasonal variation, with decreasing 
vitamin D levels in spring and winter. However, there was no significant difference by 
season in the remission phase, suggesting that patients in the active phase are more 
sensitive to seasonal factors.
There are limitations to our investigation. First, this study had a retrospective design and 
was performed in a single center with a small sample of patients. Second, the effects of sun 
exposure, dietary or over the counter vitamin D supplementation could not be measured 
accurately. In Korea, there is little exposure to sunlight between 33°N and 43°N, and there is 
not enough difference in available sunlight by season. Third, many patients lacked sufficient 
available endoscopic findings in order for us to investigate the association between vitamin 
D status and the degree of inflammation. Lastly, this study lacked bone mass densitometry 
study results and fecal calprotectin levels for most patients.
In conclusion, malnutrition and micronutrient deficiencies are common in IBD. Especially, 
vitamin D deficiency showed the greatest difference according to IBD activity, and it may be 
related to intestinal absorption as well as medication and sun exposure. IBD itself may affect 
vitamin D deficiency, and a low vitamin D level may aggravate the inflammatory response of 
IBD. Lack of micronutrients, including vitamin D, can lead to worsening of IBD and cause 
irreversible sequelae in growing children; therefore, it is important to prevent and correct 
vitamin D deficiency as soon as possible. In the future, it will be important to monitor the 
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vitamin D level more carefully in the active phase, spring, and winter in Korean pediatric 
patients with IBD and to provide sufficient vitamin D supplementation if there is a deficiency.
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